Great good! U.S. anti-cancer drug company Dendreon injects Nanjing new hundred

on the evening of August 1st, Nanjing Xinbai announced that it had completed the transfer of 100% of the shares of World Ding Bio (which owns all of Dendreon), Nanjing Xinbai held 100% of the shares of World Ding Bio, and World Ding Hong Kong has become a wholly owned subsidiary of Nanjing Xinbai This means that the first FDA-approved cell immunotherapy drug Provenge has been in the pocket of Nanjing Xinbai, Nanjing Xinbai will become the world's first FDA-approved cell immunotherapy drug Provenge A-share listed company, can not help but lament that this wave of action is real. At the end of 2017, Nanjing Xinbai on the initial disclosure of the acquisition plan, the company will acquire 100% of World Ding Hong Kong, World Ding Hong Kong's main operating assets as the United States biopharmaceutical company Dendreon's full stake, today this expectation has finally been realized With the completion of this transaction, the proportion of the triplets and their concerted actions in Nanjing Xinbai has increased from 33.10% to 42.43%. The trio's commitment to inject Dendreon into Nanjing Xinbai is a feat that is full of wisdom and courage, and it was previously widely seen as a difficult time for Dendreon injections, as Dendreon's overall deal was valued at $5,968 million According to the trading plan, Nanjing Xinbai will issue an additional 180 million shares to the triplets at a price of 33.02 yuan per share, and based on the closing price of Nanjing Xinbai 13.65 yuan on August 1, the corresponding market value of 180 million shares will be 2.46 billion yuan, a difference of 3.5 billion yuan from the 5.968 billion yuan transaction price In this huge gap, inevitably let the industry outside the people are not optimistic, and the triplets group unexpectedly sacrificed their own 3.5 billion interests, imported 5,968 million assets to the listed company Nanjing Xinbai, highlighting the controlling shareholders of its bio-medical large health listed company platform Nanjing Xinbai's top support and future expectations. Dendreon's previous strength is indisputable, as a global leader in cell immunotherapy, all revenue from its core product " tumor cell immunotherapy drug Plewe", Pleway is the first u.S Food and Drug Administration (FDA) approved the cell immunotherapy drug, after 18 years of development, in 2010 by the U.S FDA approved the market, Pleway pioneered the cell immunotherapy cancer, in the history of cell immunotherapy significance. Plewe's production process also has high technical barriers, its cell plant is the FDA approved the earliest cell plant, representing the FDA's gold standard, including the California plant is the FDA cell immunotherapy GMP (drug production quality management practices) training base, in the authority and professional aspects of no doubt. It is understood that, in addition to Plewe, Dendreon in the United States has started early prostate cancer Phase III clinical trials, and bladder cancer Phase II clinical trials, while the expansion of other cell immunotherapy including CAR-T, TCR-T, really in the platform, each initiative is sufficient to prove Dendreon's unshakable market position. What is more to be expected is that Dendreon's cell plant in Zhangjiang, Shanghai, is currently being renovated and technology shifted, and the Chinese market will be a new core driving force for the development of Dendreon cell immunotherapy in the future It also means that after dendreon injection, Nanjing Xinbai became the world's first FDA-approved cell immunopharmaceutical A-share listed company, and will make full use of Dendreon cell immunotherapy innovation research and development platform, expand new indications and product lines, fully coordinate with its original cord blood stem cell storage business, for bio-medical health to open more possible preparation, for Chinese patients are a long-awaited heavy welfare. According to public information, Dendreon's net profit for 2015 and 2017 was RMB293 million, RMB425 million and RMB446 million, respectively, with a compound annual net profit growth rate of 24% Industry insiders expect that with the injection of Dendreon into Nanjing Xinbai, will greatly thicken the nanjing Xinbai's revenue Listed companies will expand the growth space of the performance, this expectation also let Nanjing Xinbai get more market attention. Taking the 2017 annual report of the company, the net profit attributable to Nanjing Xinbai of the big health business was 483 million yuan, accounting for 71.24 percent of the company's net profit attributable to shareholders of listed companies after the company deducted, which has become the main source of the company's net profit The triplets group has previously promised that Dendreon's net profit after 2018-2020 will not be less than 530 million yuan, 600 million yuan, 660 million yuan, respectively, plus the previous injection of Nanjing Xinbai's health assets Qilu stem cells, triplets international, Ankangtong's performance commitment, the net profit attributable to Nanjing Xinbai in 2018 will reach 930 million yuan According to the announcement, Nanjing Xinbai said that the latter stage of the transaction will be approved by the CSRC in accordance with the collection of supporting funds program, to meet the requirements of no more than 10 (including 10) specific investors to raise shares to raise supporting funds of no more than 2.55 billion yuan This series of data is enough to make Nanjing Xinbai have an unshakable market position. With the development of the global anti-cancer market, the industry believes that Nanjing Xinbai is expected to become a leader in cell therapy From this point of view, nanjing's future is very promising, whether it is product services, or for the public, the acquisition of the United States Dendreon will benefit the Chinese people, but also for bio-medical health in the field of a new chapter.